Day: January 8, 2026

PRESS RELEASE                                         Share Buyback Transaction Details January 2 – January 7, 2026 Alphen aan den Rijn – January 8, 2026 – Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 120,013 of its own ordinary shares in the period from January 2, 2026, up to and including January 7, 2026, for €10.8 million and at an average share price of €89.87. These repurchases are part of the share buyback program announced on November 5, 2025, under which we intend to repurchase shares for up to € 200 million from November 6, 2025, up to February 23, 2026. The cumulative amounts repurchased in the year to date are as follows: Share Buyback 2026Period Cumulative shares repurchased in period Total consideration(€ million) Average...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential market of $7B+ in the U.S. alone Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic macular edema (DME) expected in Q2 2026 Riad Sherif, M.D., Chief Executive Officer, will present at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 1.30pm PSTZUG, Switzerland, Jan. 08, 2026 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that the transformative potential of its late-stage pipeline,...

Quarterly Production of 43,663 oz AuEq1Closing cash and bullion $232 million – $58 million increase from SeptemberQuarterly gold production of 43,663 AuEq oz, comprised of:1  Mine Group Q2(1 Oct – 31 Dec 2025) Group YTD2(1 Jul – 31 Dec 2025)    Production    Tomingley 22,089 Au oz   40,424 Au oz    Costerfield 10,790 Au oz267 Sb t11,686 AuEq oz   19,402 Au oz465 Sb t21,178 AuEq oz    Björkdal 9,888 Au oz   18,468 Au oz    Consolidated 42,767 Au oz267 Sb t43,663 AuEq oz   78,294 Au oz465 Sb t80,070 AuEq oz      Sales    Consolidated 42,709 Au oz409 Sb t44,084 AuEq oz   77,046 Au oz549 Sb t79,043 AuEq oz             Cash, bullion and listed investment balance of A$246 millionIncrease of A$55 million from the previous quarter after payment of FY25 income tax of $11 million. Alkane also received an...

                 Tarkett climate leadership recognized for the second time by a CDP A Score PARIS, FRANCE, January 8, 2026 – Tarkett, a world leader in innovative and sustainable flooring and sports surface solutions, has achieved an A Score at CDP climate rating for the second year in a row. This rating places Tarkett among the top performing companies out of 20’000 globally assessed, highlighting the company’s climate leadership. Reaching an A score shows that Tarkett has successfully implemented best practices in climate management across its operations and entire value chain. “CDP’s A List validates the strength of our climate roadmap and governance, as well as the growing expertise of our teams,” says Arnaud Marquis, Tarkett’s Chief Sustainability & Safety Officer. “We remain focused on reducing scope 3 emissions and aligning...

SUDAN LITIGATION: RULING CLEARS PATH FOR BNP PARIBAS APPEAL Paris, 8 January 2026 On the 7th of January 2026, the decision by the judge to certify the October verdict clears the path for BNP Paribas to pursue its appeal. BNP Paribas welcomes the Court’s decision as it allows the bank to pursue the procedure as planned. As BNP Paribas has consistently stated, the jury verdict is fundamentally flawed as a matter of fact and law. The Bank will demonstrate on appeal that the legal standards applied at trial were based on an erroneous application of relevant Swiss law and that a full and fair review of the facts requires dismissal of the case. Moreover, the October verdict is specific to three plaintiffs and should not have broader application. Any attempt to extrapolate or any speculation is necessarily wrong. BNP Paribas is thoroughly prepared...

Vancouver, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — NEW EARTH RESOURCES CORP. (CSE: EATH) (“New Earth” or the “Company“) is pleased to outline its planned exploration program for the SL Project, a property prospective for rare earth elements (“REE”) in the Strange Lake area of Quebec, Canada. This initiative marks a strategic first step in systematically evaluating the project’s potential, with a focus on generating regional data layers to inform future targeting and area reduction efforts. The planned regional-scale exploration program encompasses a multi-faceted approach, including regional prospecting across the property, property-wide airborne geophysics, and regional geochemical surveys. These activities are designed to identify outcrops, geological features, and potential REE mineralization...

Press release                                                                    Paris, 8 January 2026 This press release may not be distributed or published directly or indirectly in the United States or CanadaCrédit Agricole Assurances announces the launch of a tender offer for two series of subordinated fixed rate resettable notes and its intention to issue Tier 2 subordinated notesCrédit Agricole Assurances announces today the launch of a tender offer for two series of subordinated fixed rate resettable notes issued in 2016 (ISIN FR0013203734) and 2018 (ISIN FR0013312154), and its intention to issue, subject to market conditions, Tier 2 fixed rate euro subordinated notes due December 2036 (the “New Notes“). These transactions will enable Crédit Agricole Assurances to spread the maturity profile of its debt and are...

Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announces that it has been awarded an A- score by CDP, a global nonprofit that runs a leading independent environmental disclosure system for companies. The A- rating marks a strong advancement from previous years and recognizes Quadient’s successful integration of climate action into its long-term strategy. Quadient has been reporting to CDP since 2009 to assess its climate performance and benchmark itself against peers. After seven consecutive years with a B score, the move to an A- rating reflects the increased maturity of Quadient’s climate governance, its decarbonization trajectory and the concrete results already achieved. An A- rating places Quadient in CDP’s “Leadership” category and fully aligns with Quadient’s strategic...

PRESS RELEASE Regulated Information*Public disclosure of inside information VGP NV announces the launch of a capped cash tender offer for its outstandingEUR 500,000,000 1.625 per cent. fixed rate green bonds due 17 January 2027 (ISIN: BE6332786449), of which EUR 320,100,000 remains outstanding as at the date of this press release, and the intention to concurrently issue new green bonds NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE “UNITED STATES”) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933,...

Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and China New five-year data on vamorolone highlighted substantially improved safety profile with reduced vertebral fractures, lower incidence of cataracts and that normal growth rate was maintained.   With adverse effects being a key limitation of conventional corticosteroid therapy, vamorolone’s safety profile combined its comparable effectiveness, has the potential to displace existing steroid treatments Transaction advances Nxera’s mission to bring innovative medicines to patients in Japan/APAC in line with 2030 vision to build high-growth, highly profitable Japanese biopharma companyTokyo, Japan and Cambridge, UK, 8 January 2026 – Nxera Pharma Co. Ltd (“Nxera” or “the Company; TSE 4565) today announces...